Elanix Biotechnologies Competitors and Similar CompaniesClear all
Elanix Biotechnologies's competitors and similar companies include E-Qure, InspireMD, Soligenix and Procyon.
 Elanix Biotechnologies Elanix Biotechnologies develops and commercializes products for acute wound care, dermatological and gynecological applications. |  E-Qure E-QURE developed a non-invasive, electrical stimulation (ES), medical device that cures Hard-to-Heal wounds and Ulcers. |  InspireMD InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard. |  Soligenix Soligenix develops biodefense vaccines and therapeutics for the side-effects of cancer treatment and gastrointestinal diseases. |  Procyon Procyon Corporation develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems primarily in the United States. | |
Founding Date | Founding Date 2012 | Founding Date 2014 | Founding Date 2005 | Founding Date 1987 | Founding Date 1987 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Frankfurt am Main, DE HQ Epalinges, CH Nyon, CH | Locations New York, US HQ | Locations Tel Aviv-Yafo, IL HQ Winsen (Luhe), DE | Locations Princeton, US HQ | Locations Clearwater, US HQ |
Employees | Employees 1122% increase | Employees 1 | Employees 8531% increase | Employees 1422% decrease | Employees 176% increase |
Valuation ($) | Valuation ($) 6.5 m | Valuation ($) 6.9 k | Valuation ($) 63 m | Valuation ($) 8.7 m | Valuation ($) 1.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) €62k (FY, 2018) | Revenue (est.) N/A | Revenue (est.) $9m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $5m (FY, 2024) |
Cost of goods | Cost of goods €281k (FY, 2018) | Cost of goods N/A | Cost of goods $6.3m (FY, 2025) | Cost of goods N/A | Cost of goods $1.1m (FY, 2024) |
Gross profit | Gross profit (€213k) (FY, 2018) | Gross profit N/A | Gross profit $2.6m (FY, 2025) | Gross profit N/A | Gross profit $3.9m (FY, 2024) |
Net income | Net income (€3.7m) (FY, 2018) | Net income ($612.4k) (FY, 2020) | Net income ($48.8m) (FY, 2025) | Net income ($11.1m) (FY, 2025) | Net income ($341.1k) (FY, 2024) |
For sources of this data, please see the company profile
View Company Profiles
E-Qure
HQ
New York, US
Employees
1
E-QURE developed a non-invasive, electrical stimulation (ES), medical device that cures Hard-to-Heal wounds and Ulcers.
View companyInspireMD
HQ
Tel Aviv-Yafo, IL
Employees
85↑ 31% increase
InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard.
View companySoligenix
HQ
Princeton, US
Employees
14↓ 22% decrease
Soligenix develops biodefense vaccines and therapeutics for the side-effects of cancer treatment and gastrointestinal diseases.
View companyProcyon
HQ
Clearwater, US
Employees
17↑ 6% increase
Procyon Corporation develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems primarily in the United States.
View company